Washington Trust Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Washington Trust Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-83	Closed	-$3.1K	–	672
2024 Q3	$3.34K	Sell	83 -28	-25%	-$1.3K	﹤0.01%	612
2024 Q2	$5.29K	Sell	111 -147	-57%	-$6.03K	﹤0.01%	546
2024 Q1	$11.2K	Hold	258	–	–	﹤0.01%	467
2023 Q4	$13.1K	Hold	258	–	–	﹤0.01%	442
2023 Q3	$11.7K	Hold	258	–	–	﹤0.01%	443
2023 Q2	$10.6K	Sell	258 -402	-61%	-$15.4K	﹤0.01%	447
2023 Q1	$23.6K	Hold	660	–	–	﹤0.01%	396
2022 Q4	$24.9K	Sell	660 -865	-57%	-$36.4K	﹤0.01%	394
2022 Q3	$67K	Sell	1,525 -112	-7%	-$4.72K	0.01%	343
2022 Q2	$61K	Sell	1,637 -394	-19%	-$14.9K	0.01%	368
2022 Q1	$75K	Sell	2,031 -399	-16%	-$13.1K	0.01%	386
2021 Q4	$74K	Buy	+2,430	New	+$76.5K	0.01%	406

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Washington Trust Advisors's IONS Position: Q4 2024 in Review

Washington Trust Advisors sold out of Ionis Pharmaceuticals (IONS) in Q4 2024, closing a stake of 83 shares — an estimated $3.1K sold.

Washington Trust Advisors first reported a position in IONS in Q4 2021 and held it in 12 quarters. The position peaked at $75K in Q1 2022. 354 funds tracked by Wall St. Rank hold IONS as of Q4 2024.

Washington Trust Advisors reported no remaining Ionis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Washington Trust Advisors sold 83 Ionis Pharmaceuticals shares in Q4 2024, an estimated $3.1K.
Washington Trust Advisors first reported a position in Ionis Pharmaceuticals in Q4 2021 and held it in 12 quarters.
Washington Trust Advisors's Ionis Pharmaceuticals position peaked at $75K in Q1 2022.
354 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2024.

Based on Washington Trust Advisors's 13F filing for Q4 2024, filed 6 Feb 2025.